Therapeutic Response to Single-Inhaler Triple Therapies in Moderate-to-Severe COPD

REFERENCES

1. 1.↵
   Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis, and management of chronic obstructive pulmonary disease; 2020. Available at: https://goldcopd.org. Accessed July 7, 2021.
2. 2.↵
   1. Berg K,
   2. Wright JL

   . The pathology of chronic obstructive pulmonary disease: progress in the 20th and 21st centuries. Arch Pathol Lab Med 2016;140(12):1423-1428.

   OpenUrl
3. 3.↵
   1. Hogg JC,
   2. Paré PD,
   3. Hackett TL

   . The contribution of small airway obstruction to the pathogenesis of chronic obstructive pulmonary disease. Physiol Rev 2017;97(2):529-552.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Barnes PJ

   . Chronic obstructive pulmonary disease. N Engl J Med 2000;343(4):269-280.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Mannino DM,
   2. Ford ES,
   3. Redd SC

   . Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003;114(9):758-762.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Karner C,
   2. Chong J,
   3. Poole P

   . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;2014(7):CD009285.

   OpenUrl
7. 7.
   1. Trivedi R,
   2. Richard N,
   3. Mehta R,
   4. Church A

   . Umeclidinium in patients with COPD: a randomized, placebo-controlled study. Eur Respir J 2014;43(1):72-81.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Tashkin DP,
   2. Celli B,
   3. Senn S,
   4. Burkhart D,
   5. Kesten S,
   6. Menjoge S,
   7. et al

   ; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-1554.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Farne HA,
   2. Cates CJ

   . Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015;10:CD008989.

   OpenUrl
10. 10.↵
    1. Cazzola M,
    2. Molimard M

    . The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010;23(4):257-267.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Quint JK,
    2. Venerus A,
    3. O’Leary C,
    4. Myland M,
    5. Holmgren U,
    6. Varghese P,
    7. Cabrera C

    . Prescribing pathways to triple therapy: a retrospective observational study of adults with chronic obstructive pulmonary disease in the UK. Int J Chron Obstruct Pulmon Dis 2020;15:3261-3271.

    OpenUrl
12. 12.↵
    1. Bogart M,
    2. Stanford RH,
    3. Reinsch T,
    4. Hull M,
    5. Buikema A,
    6. Hulbert E

    . Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: a retrospective study. Respir Med 2018;142:73-80.

    OpenUrl
13. 13.↵
    1. Mammen MJ,
    2. Lloyd DR,
    3. Kumar S,
    4. Ahmed AS,
    5. Pai V,
    6. Kunadharaju R,
    7. et al

    . Triple therapy versus dual or monotherapy with long-acting bronchodilators for chronic obstructive pulmonary disease. a systematic review and meta-analysis. Ann Am Thorac Soc 2020;17(10):1308-1318.

    OpenUrl
14. 14.↵
    European Medicines Agency. Summary of product characteristics. Available at: https://www.ema.europa.eu/. Accessed June 30, 2022.
15. 15.↵
    1. Bestall JC,
    2. Paul EA,
    3. Garrod R,
    4. Garnham R,
    5. Jones PW,
    6. Wedzicha JA

    . Usefulness of the Medical Research Council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54(7):581-586.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Jones PW,
    2. Harding G,
    3. Berry P,
    4. Wiklund I,
    5. Chen WH,
    6. Kline Leidy N

    . Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34(3):648-654.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Tantucci C,
    2. Pinelli V,
    3. Cossi S,
    4. Guerini M,
    5. Donato F,
    6. Grassi V

    ; The SARA Study Group. Reference values and repeatability of inspiratory capacity for men and women aged 65–85. Respir Med 2006;100(5):871-877.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Donohue JF

    . Minimal clinically important differences in COPD lung function. COPD 2005;2(1):111-124.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. O’Donnell DE,
    2. Revill SM,
    3. Webb KA

    . Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164(5):770-777.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Calverley PM,
    2. Koulouris NG

    . Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005;25(1):186-199.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Jo YS,
    2. Kim SK,
    3. Park SJ,
    4. Um S-J,
    5. Park Y-B,
    6. Jung KS,
    7. et al

    . Longitudinal change of FEV₁ and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD. Int J Chron Obstruct Pulmon Dis 2019;14:361-369.

    OpenUrl
22. 22.↵
    1. Freitas CG,
    2. Pereira CA,
    3. Viegas CA

    . Inspiratory capacity, exercise limitation, markers of severity, and prognostic factors in chronic obstructive pulmonary disease. J Bras Pneumol 2007;33(4):389-396.

    OpenUrlPubMed
23. 23.↵
    1. Tantucci C,
    2. Donati P,
    3. Nicosia F,
    4. Bertella E,
    5. Redolfi S,
    6. De VM,
    7. et al

    . Inspiratory capacity predicts mortality in patients with chronic obstructive pulmonary disease. Respir Med 2008;102(4):613-619.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Ferguson GT,
    2. Rabe KF,
    3. Martinez FJ,
    4. Fabbri LM,
    5. Wang C,
    6. Ichinose M,
    7. et al

    . Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multi-center, phase 3 randomized controlled trial. Lancet Respir Med 2018;6(10):747-758.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Ichinose M,
    2. Fukushima Y,
    3. Inoue Y,
    4. Hataji O,
    5. Ferguson GT,
    6. Rabe KF,
    7. et al

    . Efficacy and safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology in Japanese patients with COPD: a subgroup analysis of the KRONOS study. Int J Chron Obstruct Pulmon Dis 2019;14:2979-2991.

    OpenUrl
26. 26.↵
    1. Lipson DA,
    2. Barnhart F,
    3. Brealey N,
    4. Brooks J,
    5. Criner GJ,
    6. Day NC,
    7. et al

    ; IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018;378(18):1671-1680.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Kato M,
    2. Tomii K,
    3. Hashimoto K,
    4. Nezu Y,
    5. Ishii T,
    6. Jones CE,
    7. et al

    . The IMPACT study - single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: efficacy and safety in a Japanese population. Int J Chron Obstruct Pulmon Dis 2019;14:2849-2861.

    OpenUrl
28. 28.↵
    1. Muro S,
    2. Sugiura H,
    3. Darken P,
    4. Dorinsky P

    . Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts. Respir Res 2021;22(1):187.

    OpenUrl
29. 29.↵
    1. Daley-Yates P,
    2. Brealey N,
    3. Thomas S,
    4. Austin D,
    5. Shabbir S,
    6. Harrison T,
    7. et al

    . Therapeutic index of inhaled corticosteroids in asthma: a dose-response comparison on airway hyper-responsiveness and adrenal axis suppression. Br J Clin Pharmacol 2021;87(2):483-493.

    OpenUrl
30. 30.↵
    1. Maltais F,
    2. Ferguson GT,
    3. Feldman GJ,
    4. Deslee G,
    5. Bourdin A,
    6. Fjällbrant H,
    7. et al

    . A randomized, double-blind, double-dummy study of glycopyrrolate/formoterol fumarate metered dose inhaler relative to umeclidinium/vilanterol dry powder inhaler in COPD. Adv Ther 2019;36(9):2434-2449.

    OpenUrl
31. 31.↵
    1. Fujimoto K,
    2. Yamazaki H,
    3. Ura M,
    4. Kitaguchi Y

    . Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study. Int J Chron Obstruct Pulmon Dis 2017;12:3195-3201.

    OpenUrl
32. 32.↵
    1. Leivo-Korpela S,
    2. Lehtimäki L,
    3. Vuolteenaho K,
    4. Nieminen R,
    5. Kööbi L,
    6. Järvenpääet R,
    7. et al

    . Adiponectin is associated with dynamic hyperinflation and a favorable response to inhaled glucocorticoids in patients with COPD. Respir Med 2014;108(1):122-128.

    OpenUrl
33. 33.↵
    1. Usmani OS,
    2. Roche N,
    3. Jenkins M,
    4. Stjepanovic N,
    5. Mack P,
    6. De Backer W

    . Consistent pulmonary drug delivery with whole lung deposition using the aerosphere inhaler: a review of the evidence. Int J Chron Obstruct Pulmon Dis 2021;16:113-124.

    OpenUrlPubMed
34. 34.↵
    1. Usmani OS,
    2. Dhand R,
    3. Lavorini F,
    4. Price D

    . Why we should target small airways disease in our management of chronic obstructive pulmonary disease. Mayo Clin Proc 2021;96(9):2448-2463.

    OpenUrl
35. 35.↵
    1. Bhatt SP,
    2. Soler X,
    3. Wang X,
    4. Murray S,
    5. Anzueto AR,
    6. Beaty TH,
    7. et al

    ; COPDGene Investigators. Association between functional small airway disease and FEV₁ decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2016;194(2):178-184.

    OpenUrlCrossRefPubMed